Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention

Adherence, Medication Clinical Trial

Official title:

Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention for Breast Cancer Patients Treated With Aromatase Inhibitors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03739983
• Other study ID #: UW17032
• Secondary ID: 2018-0633A532820
• Status: Terminated
• Phase: Phase 2
• Start date: November 19, 2019
• Est. completion date: March 10, 2020

Study information

• Verified date: August 2021
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Breast cancer patients commonly take medications to reduce the risk of recurrence, including aromatase inhibitors (AIs). AIs can cause significant side effects that reduce patient adherence. Early discontinuation of AI therapy results in an increased risk of cancer recurrence and increased risk of breast cancer-related death. Common side effects include vaginal dryness and vulvovaginal atrophy leading to worsening sexual function. To increase AI adherence, the investigators will study a non-pharmaceutical Vaginal Renewal Program (VRP) aimed at stimulating nitric oxide production to consequently increase vaginal lubrication, and improve the symptoms of vulvovaginal atrophy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: March 10, 2020
• Est. primary completion date: March 10, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have completed active primary treatment
• defined as surgery chemotherapy and/or radiation for the treatment of breast cancer
• Does not include immunotherapy or other targeted therapies such as trastuzumab, CDK 4/6 or mTOR inhibitors
• Have been receiving AIs for at least 6 months prior to enrollment
• Plan to continue AIs for an additional 3 months
• Amenorrhea for at least 12 months at enrollment
• Participants must be able to read and write in English
• Participants must have < 2% superficial vaginal cells on cytologic evaluation

Exclusion Criteria:

• Pre-existing hypertonic pelvic floor dysfunction identified in the medical record
• Unresolved or recurrent vaginismus identified in the medical record
• Aversion to touching one's own body, including genitals, or using vibration therapy on the genitals
• Currently receiving estrogen therapy, including topical and/or systemic estrogens
• Have received estrogen therapy within 6 months of study enrollment, including topical and/or systemic estrogens
• Any surgical procedure to the vagina or vulva, excluding office biopsies, within the previous 12 months
• Receipt of pelvic or vaginal or vulvar radiation therapy within the 12 months prior to enrollment or if the subject is anticipated to receive radiation targeted to any of these 3 locations within 6 months following enrollment
• Any use of the VRP off study within the last 6 months

Related Conditions & MeSH terms

• Adherence, Medication

Intervention

Device:
• Vaginal Renewal Program
Therapeutic vibrating wand.

Locations

Country	Name	City	State
United States	University of Wisconsin Carbone Cancer Center	Madison	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
University of Wisconsin, Madison	American Cancer Society, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adherence to AI Therapy	Adherence to AI therapy will be determined using patient-reported logs.	up to 12 weeks
Primary	Percentage of Superficial Vaginal Cells	The investigators expect the percentage of superficial vaginal cells to be greater at the post-intervention time point when compared to the pre-intervention time point. If the percentage of superficial vaginal cells is = 4% following the intervention, then the response will be considered positive.	up to 12 weeks
Secondary	Change in Vaginal pH	Changes in the vaginal pH will be analyzed to determine the extent to which the changes correlate with changes in the primary outcome and with patient reported outcomes. Given the longitudinal nature of the study, linear and generalized linear mixed effects models will be fit to the data gathered. The restricted maximum likelihood (REML) criterion will be used and 95% semi-parametrically bootstrapped confidence intervals will be obtained for all parameters. All statistical analyses will be conducted using R (R Core Team 2014).	up to 12 weeks
Secondary	Patient Reported Outcomes: Number of Subjects With Improved Anxiety	Number of subjects with improved anxiety outcomes per over baseline. The PROMIS (Patient Reported Outcomes Measurement Information System) Emotional Distress - Anxiety scale measures patient perceived changes in anxiety and includes 8 questions that they answer about their emotional state in the past 7 days. Descriptive answers are scored from 1 (never) to 5 (always). The total possible range of scores is from 8-40, with higher scores indicating a worse outcome.	up to 12 weeks
Secondary	Patient Reported Outcomes: Number of Subjects With Improved Depression	Number of subjects with improved depression outcomes over baseline. The PROMIS (Patient Reported Outcomes Measurement Information System) Emotional Distress - Depression scale measures patient perceived changes in depression and includes 8 questions that they answer about their emotional state in the past 7 days. Descriptive answers are scored from 1 (never) to 5 (always). The total possible range of scores is from 8-40, with higher scores indicating a worse outcome.	up to 12 weeks
Secondary	Patient Reported Outcomes: Number of Subjects With Improved Sexual Function Outcomes	Number of subjects with improved sexual function outcomes over baseline. The PROMIS (Patient Reported Outcomes Measurement Information System) Sexual Function Profile scale measures patient perceived changes in sexual function and includes 10 questions that they answer about their functional state. Descriptive answers include 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', or 'Very', and will be summarized with descriptive statistics.	up to 12 weeks
Secondary	Patient Reported Outcomes: Number of Subjects With Improved Global Health	Number of subjects with improved global health over baseline. The PROMIS (Patient Reported Outcomes Measurement Information System) Global Health scale measures patient perceived changes in health and includes 10 questions that they answer about their perceived health in the past 7 days. Higher scores indicate a higher perceived level of overall health.	up to 12 weeks
Secondary	Patient Reported Outcomes: Number of Subjects With Improved Sex Life	Number of subjects with improved sex life over baseline. The PROMIS (Patient Reported Outcomes Measurement Information System) Global Satisfaction with Sex Life scale measures patient perceived changes in the satisfaction of their sex life and includes 7 questions that they answer about their perceived state. Descriptive answers include 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', or 'Very', and will be summarized with descriptive statistics.	up to 12 weeks

External Links

•   University of Wisconsin Carbone Cancer Center